Savara (NSDQ:SVRA) announced today that it priced an underwritten public offering of common stock at approximately $113 million. Austin, Texas-based Savara — an orphan lung disease treatment company with an inhaled formulation of recombinant human GM-CSF — is offering nearly 45.8 million shares of its common stock to the public for $1.45 per share, according to […]
AFYX Therapeutics touts study results for biodegradable oral adhesive patch
AFYX Therapeutics announced today that a study observed successful transmucosal delivery of a corticosteroid with its Rivelin patch. The Rivelin clobetasol patch (Rivelin-CLO) is a novel adhesive patch designed to deliver a therapeutic agent to wet tissue surfaces. The study, published in The European Journal of Oral Sciences, was the first to show the successful […]
Xeris Pharmaceuticals prices $27M offering
Xeris Pharmaceuticals (NSDQ:XERS) announced today that it priced a registered direct offering of common stock at $27 million. Chicago-based Xeris is offering nearly 6.6 million shares of common stock to funds managed by Deerfield Management Company, which are existing investors in the company, according to a news release. The offering is priced at $4.12 per share, […]
AVEO Oncology names new chief commercial officer
AVEO Oncology (NSDQ:AVEO) announced that it appointed Mike Ferraresso as its new chief commercial officer. Boston-based AVEO Oncology said in a news release that Feraresso will manage the company’s commercial strategy and operations, including the commercialization of Fotivda (tivozanib), a differentiated, oral, once-daily, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). Fotivda is […]
Takeda to acquire T-cell engager therapy maker Maverick Therapeutics for $525M
Takeda Pharmaceutical (NYSE:TAK) announced that it is acquiring Maverick Therapeutics in a deal worth up to $525 million. Osaka, Japan-based Takeda exercised its option to acquire Maverick and its T-cell engager Cobra platform and development portfolio, including multiple solid tumor treatments in various clinical stages. Following the closing of the deal, Maverick employees will join […]
Neurelis closes $114M Series D for diazepam nasal spray
Neurelis announced today that it closed a $114 million Series D financing round to support its lead orphan drug product. San Diego-based Neurelis’ Valtoco (diazepam nasal spray) is a proprietary formulation incorporating the science of Intravail transmucosal absorption enhancement technology. The drug enables the noninvasive delivery of a range of drugs, while the company focuses […]
Cure Pharmaceutical launches antiviral, anti-seizure development programs
Drug delivery technology developer Cure Pharmaceutical (OTC:CURR) announced today that it launched two new clinical development programs. Oxnard, Calif.-based Cure’s first new launch is an antiviral clinical development program for loading a known active pharmaceutical ingredient (API) onto its Curefilm patented drug delivery platform that optimizes the absorption and metabolism of therapeutic devices, according to […]
Eitan Medical wins EU clearance for Sapphire infusion pump
Eitan Medical announced that it received European Union Medical Device Recognition (MDR) certification for its Sapphire infusion pump. Approval for the Sapphire infusion pump, along with its accessories and administration sets, was granted in January 2021, according to a news release. The certification is EU MDR 2017/45. Sapphire includes upgraded Rev15 software, also EU MDR […]
Soleo Health to administer Givlaari injections
Soleo Health announced that it joined the treatment center directory for Givlaari and can now administer it for adults with AHP. Givlaari, managed by Alnylam Pharmaceuticals (NSDQ:ALNY), is the first FDA-approved treatment for acute hepatic porphyria (AHP) in adults. The once-monthly injection for subcutaneous use reduces the levels of neurotoxins associated with AHP attacks and […]
NeuroRX, TFF Pharmaceuticals enter feasibility agreement for Zyesami dry powder for COVID-19
NeuroRx and TFF Pharmaceuticals (NSDQ:TFFP) announced a feasibility agreement for the former’s Zyesami therapeutic. Zyesami (aviptadil, synthetic VIP) materials are set to be delivered to TFF to perform feasibility formulation work and testing in an effort to identify an optimal, long-term, stable formulation of Zyesami into a dry powder form for aerosol delivery directly to […]
